Week in Review: Korea's Hanmi Signs $960 Million Deal with Janssen

Hanmi Pharma of South Korea announced its fourth major out-licensing this year, a $960 million deal with Janssen for a diabetes-obesity drug; Denmark's LEO Pharma paid $727 million for global rights to Astellas' dermatology assets; Medtronic and Sequoia Capital partnered on a $60 million investment fund to support China device startups; BioDuro, a China-US CRO, merged its US operations with Formex, a CMO located in San Diego; WuXi PharmaTech and Eli Lilly will collaborate to develop a Lilly cardiovascular drug in China; ASLAN Pharma of Singapore and Hyundai Pharm will jointly develop an ASLAN molecule for cancer in South Korea; China will once again allow IPOs after a four-month suspension to prop up stock prices; Cellular Biomedicine opened a GMP manufacturing facility in the PKUCare Industrial Park of Beijing; and Hutchison MediPharma started a US Phase I clinical trial of sulfatinib in patients with solid tumors. More details....  Stock Symbols: (KRX: 1289400) (NYSE: MDT) (NYSE: WX) (NYSE: LLY) (NSDQ: CBMG) (AIM: HCM) Share this with colleagues: // //